Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on July 22, 2025. The filing addresses a material event regarding the Company's listing status on the Nasdaq Stock Market. The Company is incorporated in Nevada and its common stock (Symbol: RLMD) is registered on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes Versus Prior Period
- Listing Transfer: Nasdaq approved the transfer of the Company's listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of business on July 24, 2025.
- Compliance Status: The Company failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days ended January 17, 2025. The initial 180-day compliance period expired on July 21, 2025, without the Company regaining compliance.
- Extension Granted: Nasdaq granted a new 180-day compliance period extending until January 19, 2026, under Nasdaq Listing Rule 5550(a)(2).
Guidance, Outlook, and Risks
Management Commentary: The Company intends to actively monitor its bid price and take all reasonable measures to regain compliance with the minimum bid price requirement ($1.00 for 10 consecutive business days) before the new deadline.
Risks and Contingencies:
- There is no assurance that the Company will be able to regain or maintain compliance with Nasdaq listing standards.
- Failure to regain compliance could result in delisting.
- Forward-looking statements regarding the ability to regain compliance are subject to substantial risks and uncertainties.
Important Facts for Investor Verification
- Verify the effective date of the listing transfer to the Nasdaq Capital Market (July 24, 2025).
- Monitor the stock's closing bid price to ensure it meets the $1.00 threshold for 10 consecutive business days prior to January 19, 2026.
- Review the Company's most recent Form 10-K and 10-Q for detailed financial health and risk factors not included in this 8-K.
- Confirm whether the Company has announced any specific corporate actions (e.g., reverse stock split) intended to address the bid price deficiency.